Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer
Gastric cancer is a leading cause of cancer-related deaths worldwide. Recently, clinical studies have demonstrated that many of those with advanced gastric cancer are responsive to immune checkpoint antibody therapy, although the median survival even with these new agents is less than 12 months for...
Saved in:
Main Authors: | Jill P. Smith, Hong Cao, Wenqiang Chen, Kanwal Mahmood, Teresa Phillips, Lynda Sutton, Allen Cato |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/3a3572a1ffa44036b51f169e5df25342 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gastrin-17 Combined with CEA, CA12-5 and CA19-9 Improves the Sensitivity for the Diagnosis of Gastric Cancer
by: Wang Z, et al.
Published: (2021) -
Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm
by: Shan Yu, et al.
Published: (2021) -
The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival
by: Anouk Rijken, et al.
Published: (2021) -
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
by: Alberto Bongiovanni, et al.
Published: (2021) -
Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
by: Cor J. Ravensbergen, et al.
Published: (2021)